Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on March 16, 2021. The filing serves to announce the company's financial results for the three and twelve months ended December 31, 2020. The registrant is incorporated in California and its common stock is listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K document.
Material Changes
The filing does not detail specific material changes versus prior periods within the text provided. It directs readers to the attached press release (Exhibit 99.1) for the full announcement of results for the periods ended December 31, 2020.
Guidance, Outlook, and Risks
The document includes a standard forward-looking statements disclaimer. It warns that statements containing words such as "may," "will," "believes," "plans," "intends," "anticipates," "expects," and "estimates" are forward-looking and subject to risks. The filing states that undue reliance should not be placed on these statements and that the company disclaims any obligation to update them. Specific risks are referenced as being detailed in the company's Annual Report on Form 10-K under the heading "Risk Factors."
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 16, 2021) for actual revenue, net income, and cash flow figures.
- Consult the most recent Form 10-K to understand the specific risk factors referenced in the forward-looking statements.
- Verify the company's status as an emerging growth company, as indicated by the checked box in the filing.
- Confirm that the financial data in the press release aligns with the company's historical performance trends.